Business Wire

BehavioSec Expands Portfolio and Opens Market Access with Another Industry First

Share

BehavioSec, industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced that it has extended its patented technology and BehavioSense platform into a SOC/ISO compliant, hosted-version and a cloud-native, SaaS version. These new versions will help more organizations meet compliance and cloud mandates, support frictionless multi-factor authentication (MFA), and gain access to the market’s most advanced behavioral biometrics technology – which until now – has only been employed within the world’s largest banks, e-Identity providers, and online retailers.

According to the recent July release of the 2021 Gartner ® Market Guide for Online Fraud Detection, “The convergence between online fraud detection (OFD), identity proofing and authentication continues with many organizations applying OFD capabilities to mitigate risk in identity proofing and authentication events.” The report further adds, “Banks are becoming increasingly comfortable with using vendor-hosted or SaaS solutions from vendors for transaction monitoring, which is a OFD capability that has traditionally been deployed on-premises in banking environments.” 1

As biometrics technology adoption increases and more companies look to hosted and SaaS-based solutions, the new SaaS-version of the company’s BehavioSense platform is the market’s first to offer comprehensive behavioral biometrics for MFA in this lightweight, self-service form factor. Unlike other SaaS-based solutions that may specialize in just web interfaces or typing, this new platform brings the company’s deep insights across device types and human interaction to identify unique humans during the authentication process.

“As more organizations move through digital transformation projects, adopting solutions that can offer accuracy, protect privacy, reduce friction – and be agile – is critical,” said Ed Amoroso, Founder and CEO of analyst firm TAG CYBER and former Chief Security Officer at AT&T. “This is especially important for organizations with continuous delivery models for their online services or those concerned with insider threat in our current remote/hybrid work environments.”

The new SaaS packaging is more than a port – it is purpose-built to streamline the BehavioSec API and feature set to offer transparent and passwordless MFA, reduction of step-ups, and replacement of legacy technologies like knowledge-based challenges. In particular, while the new service may seamlessly work in conjunction with one-time passwords (OTP), it can also serve as the means to retire OTP – as OTPs and SMS codes are notorious for their added costs to both business and consumer, friction-full experiences, and recently – vulnerability to a rising trend of SMS fraud.

To ensure rapid time-to-value, the new SaaS solution offers an especially lightweight SDK for easy deployment and integration with Identity & Access Management (IAM) platforms already implemented within customer environments for business, consumer, or workforce protection.

“The vision at the outset of this project was to bring this powerful technology used by the largest financial institutions to a broader audience needing a solution for digital identity protection that supports both compliance and privacy protection,” said BehavioSec VP of Products, Jordan Blake. “And it is not enough to make it available. It has to be highly deployable and user friendly, too - offering high value.”

In addition to the new SaaS version, the commercial release of the vendor-hosted BehavioSense service offers sophisticated fraud organizations the full breadth and depth of BehavioSec fraud prevention technology in a Type 2 SOC 2 and ISO 27001 compliant environment. While the company’s software-based BehavioSense platform has always been fully cloud-compatible for deployment within customer environments (including public cloud), this release comes after the company’s April announcement of Type 1 SOC 2 certification and the subsequent completion of the full Type 2 and ISO requirements.

Today’s announcement follows the company’s 2020 performance that saw a successful 300% growth and a series of developments during the first half of 2021, including significant platform updates and recently, key patent grants. As the company continues to invest in technology innovation and expansion of its go-to-market capabilities, the tripling of its platform footprint into a portfolio play provides a foundation to offer customers greater flexibility with multiple packaging and licensing options tightly aligned to customer requirements and phased implementations.

The new BehavioSense SaaS platform is available now in controlled release with general availability slated for later this year. A free version of the product offering immediate access for developers may be requested online on the BehavioSec website. Customers interested in free, full production trials of any of the company’s solutions may contact the BehavioSec sales team at sales@behaviosec.com. For more information on these new solutions, visit www.behaviosec.com/platform.

1 Gartner, “Market Guide for Online Fraud Detection” Akif Khan, Jonathan Care, 12 July 2021

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About BehavioSec

BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today. Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.

Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

W2 Communications for BehavioSec
Carrie Vanbuskirk
pr@behaviosec.com
703 218 3555

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

HiddenA line styled icon from Orion Icon Library.Eye